

# Afdeling for Patologi, Herlev Hospital

2023

## Molekylærbiologiske QC shemes

### NGS og PCR

| Analyse                  | Seneste valideret | Scheme udbyder                    | Resultat  | Deltagelseshistorik                                  |
|--------------------------|-------------------|-----------------------------------|-----------|------------------------------------------------------|
| Colon Extended MSI - MMR | 2023              | UK NEQAS Molecular Genetics       | Valideret | 2023, 2022, 2021, 2020                               |
| Colon Scheme             | 2018              | EQA European Society of Pathology | Valideret | 2018 ,2017, 2016, 2015, 2014, 2013, 2012, 2011, 2010 |
| Euroclonality            | 2021              | EQA European Society of Pathology | Valideret | 2021, 2020, 2019, 2018 ,2014                         |
| Lung Comprehensive       | 2022              | UK NEQAS Molecular Genetics       | Valideret | 2022, 2020                                           |
| Lung Scheme              | 2019              | UK NEQAS Molecular Genetics       | Valideret | 2019, 2018 ,2017                                     |
| BRCA somatic             | 2022              | UK NEQAS Molecular Genetics       | Valideret | 2022, 2021, 2020, 2019, 2018 ,2017                   |
| BRCA germline            | 2020              | UK NEQAS Molecular Genetics       | Valideret | 2022, 2021 ,2020, 2019, 2018 ,2017                   |

# Afdeling for Patologi, Herlev Hospital

2023

|                                                                  |      |                                     |                 |                                          |
|------------------------------------------------------------------|------|-------------------------------------|-----------------|------------------------------------------|
| GIST (geno)                                                      | 2022 | UK NEQAS Molecular Genetics         | Valideret       | 2022, 2021, 2018, 2017, 2016, 2015, 2014 |
| Melanoma                                                         | 2021 | UK NEQAS Molecular Genetics         | Valideret       | 2022, 2021, 2018, 2017, 2016, 2015, 2014 |
| MSI (geno)                                                       | 2018 | UK NEQAS Molecular Genetics         | Valideret       | 2018, 2017, 2016                         |
| NGS Pilot Somatic                                                | 2017 | UK NEQAS Molecular Genetics         | uden bedømmelse | 2017, 2016                               |
| Molecular Pathology reference sample                             | 2017 | UK NEQAS Molecular Genetics         | uden bedømmelse | 2017, 2016                               |
| Molecular Genetics Participants Meeting                          | 2014 | UK NEQAS Molecular Genetics         | uden bedømmelse | 2014                                     |
| IG (IGHV, IGHD, IGHJ)                                            | 2017 | European research initiative on CLL | Valideret       | 2017                                     |
| MMR                                                              | 2019 | UK NEQAS Molecular Genetics         | Valideret       | 2019, 2018                               |
| BRCA Hereditary Breast and Ovarian Cancer                        | 2019 | UK NEQAS Molecular Genetics         | Valideret       | 2019                                     |
| Acute Myeloid Leukaemia and Myelodysplastic Syndrome Gene Panels | 2020 | UK NEQAS Molecular Genetics         | Valideret       | 2020                                     |

# Afdeling for Patologi, Herlev Hospital

2023

|                                                            |      |                             |                        |                        |
|------------------------------------------------------------|------|-----------------------------|------------------------|------------------------|
| Hereditary Cancer                                          | 2020 | UK NEQAS Molecular Genetics | Valideret              | 2020                   |
| cfDNA in Lung Cancer                                       | 2022 | UK NEQAS Molecular Genetics | Valideret              | 2022, 2021             |
| NTRK pilot                                                 | 2022 | UK NEQAS Molecular Genetics | uden bedømmelse (100%) | 2022, 2021             |
| Prostate pilot                                             | 2021 | UK NEQAS Molecular Genetics | uden bedømmelse        | 2021                   |
| DNA extraction from fresh frozen tissue                    | 2022 | UK NEQAS Molecular Genetics | Valideret              | 2022                   |
| DNA extraction from FFPE                                   | 2022 | UK NEQAS Molecular Genetics | Valideret              | 2022, 2021             |
| DNA quantification                                         | 2023 | UK NEQAS Molecular Genetics | Valideret              | 2023                   |
| Breast cancer PIK3CA pilot                                 | 2022 | UK NEQAS Molecular Genetics | uden bedømmelse (100%) | 2022, 2021             |
| Acute Myeloid Leukaemia and Myelodysplastic Syndrome pilot | 2022 | UK NEQAS Molecular Genetics | uden bedømmelse        | 2022, 2021, 2020, 2019 |
| HRD National HRD testing DMPG                              | 2025 | Herlev Hospital             | Intern bedømmelse      | 2025                   |

# Afdeling for Patologi, Herlev Hospital

2023

\*Udgået eller erstattet EQA schemes

## IHC og FISH

| Analyse                                     | Hyppig-<br>hed | Scheme udbyder | Resultat    |  |
|---------------------------------------------|----------------|----------------|-------------|--|
| General Module (5 - 6 antistoffer pr. gang) | 3 x årligt     | NordiQC*       | Valideret** |  |
| Breast Cancer Module                        | 2 x årligt     | NordiQC*       | Valideret** |  |
| HER2-ISH Module                             | 2 x årligt     | NordiQC*       | Valideret** |  |
| Companion Diagnostics Module (PD-L1)        | 2 x årligt     | NordiQC*       | Valideret** |  |

\*NordiQC: Nordic immunohistochemical Quality Control, [www.nordi-qc.org](http://www.nordi-qc.org)

# Afdeling for Patologi, Herlev Hospital 2023

## \*\*Assessment marks

Provided the use of an appropriate antibody, each stain is marked as optimal, good, borderline or poor.

- **Optimal staining:** The staining is considered perfect or close to perfect in all of the included tissues.
- **Good staining:** The staining is considered fully acceptable in all of the included tissues. However, the protocol may be optimized to ensure the best staining intensity and signal-to-noise ratio.
- **Borderline staining:** The staining is considered insufficient, e.g., because of a generally too weak staining or a false negative staining of one of the included tissues, or a false positive staining reaction. The protocol should be optimized.
- **Poor staining:** The staining is considered very insufficient e.g., because of false negative staining of several of the included tissues, or a marked false positive staining reaction. An optimization of the protocol is urgently needed.

|                                                                                                                                       |                                                  |                                                                          |      |
|---------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------------------------------|------|
| Arrangør af national HRD scheme - Quality Assessment Study for Danish Molecular Pathology<br><br>Laboratories Performing HRD Analysis | Herlev- og Gentofte<br><br>Unviversitetshospital | Resultat: God overensstemmelse<br><br>imellem de deltagende laboratorier | 2025 |
|---------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------------------------------|------|